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LO-A.10 SYNCHRONOUS PRIMARY
COLORECTAL CANCER AND LIVER
METASTASIS: IMPACT OF OPERATIVE
APPROACH ON CLINICAL OUTCOMES
AND HOSPITAL COSTS
A. Ejaz, G. Spolverato, E. Semenov, D. Tanner, J. Hundt
and T. M. Pawlik
Johns Hopkins Hopsital, Baltimore, MD
Introduction: Management of patients with colorectal
cancer (CRC) and synchronous colorectal liver metastasis
(sCRLM) remains controversial. We examined the clinical
and economic impact of managing sCRLM with a staged
versus simultaneous approach.
Method: We identified 229 patients treated for sCRLM
between 1990–2012. Clinicopathologic features, peri-
operative outcomes, and total hospital costs(inflation-
adjusted) were collected and analyzed.
Results: 118 (52%) patients underwent a staged approach
while 111 (48%) had a simultaneous CRC and liver opera-
tion. Overall intra-hepatic tumor burden was similar among
patients treated with staged versus simultaneous approach
(largest metastasis: 3.2 cm vs. 1.9 cm; number of metastasis:
2 vs. 2; both P > 0.05). Liver-directed therapy included hepa-
tectomy (73%), ablation alone (3%) or combined resec-
tion + ablation (24%). A major hepatectomy (>3 segments)
was more common with a staged approach (54% vs.
31%;P < 0.001); 43% of patients underwent an extended
hepatic resection(staged, n = 64 vs. simultaneous, n = 35).
There were 68 (30%) patients who had a post-operative com-
plication with no difference in the staged (38%) vs. simulta-
neous (27%) groups (P > 0.05). 90-day mortality was 1.7%
(staged, 1.7% vs. simultaneous, 1.8%; P = 0.94). Median
total length of hospitalization was longer in the staged (12.5
days) versus simultaneous(7.0 days) group (P < 0.001).
Median total hospital costs were also higher among patients
undergoing a staged approach ($57,821) compared with a
simultaneous operation ($27,401) (P < 0.01). Long-term out-
comes were similar(5-year disease-free survival: staged,
39.8% vs. simultaneous, 48.6%; P = 0.61).
Conclusion: Patients with sCRLM managed with either a
staged or simultaneous approach had comparable peri-
operative and long-term outcomes. However, patients treated
with a simultaneous approach spent significantly fewer days
in the hospital and had a median cost savings of $30,420.
When appropriate, the simultaneous approach for sCRLM
should be preferred.
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LO-B.01 PATIENT SELECTION AND THE
VOLUME EFFECT IN PANCREATIC
SURGERY: UNEQUAL BENEFITS?
L. A. Bliss1,3, C. J. Yang1, K. Lagisetty1, Z. Chau2, S. Ng1,
T. S. Kent1, A. J. Moser1, D. W. McFadden3, M. P. Callery1
and J. F. Tseng1
1Beth Israel Deaconess Medical Center, Boston, MA;
2University Of Massachusetts Medical School, Worcester,
MA; 3University Of Connecticut Health Center,
Farmington, CT
Background: The volume effect in pancreatic surgery is
well established. Regionalization to high-volume centers has
been proposed. The effect of volume-based proposals on
practice patterns is unknown.
Methods: Retrospective review of patients undergoing pan-
createctomy in Nationwide Inpatient Sample (NIS) 2004–
2011. Inpatient mortality and complication rates calculated.
Patients stratified by annual center volume (low <5, medium
5–18, high >18) based on prior publication. Multivariable
regression model evaluated predictors of morbidity, mortality
and resection at a high-volume center.
Results: 129,609 patients underwent pancreatectomy.
Crude inpatient mortality rate was 4.3%, decreasing over
2004–2011 (5.2% to 3.1%, p < 0.0001). 36.0% experienced
complications. 65.2% underwent resection at high-volume
centers. In 2004, low-, medium-, and high-volume centers
resected 16.3%, 26.8%, and 56.9% of patients, compared
with 7.65%, 20.7%, and 71.7% in 2011. High-volume centers
had lower mortality (3.2% versus 6.5%, p < 0.0001), fewer
complications (33.0% versus 41.6%, p < 0.0001) and shorter
median length of stay (9 versus 11 days, p < 0.0001).
However, patients at medium- or low-volume centers had
more co-morbidities (40.9% versus 37.2% with Elixhauser
>2, p = 0.0020), lower rates of private insurance (40.0%
versus 43.8%, p = 0.0030) and more non-elective admissions
(30.6% versus 17.8%, p < 0.0001).
Conclusion: Overall, mortality after pancreatectomy con-
tinues to improve. Despite a shift to high-volume hospitals, a
substantial cohort still receives care outside of these centers.
Patients receiving non-high-volume care demonstrate less
favorable comorbidities, insurance, and urgency of opera-
tion. The implications are twofold: already disadvantaged
patients may not benefit from a high-volume effect; and
patients predisposed to do well may contribute to observed
superior outcomes at high-volume centers.
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LO-B.02 REDUCING READMISSIONS
FOLLOWING PANCREATECTOMY:
COORDINATION OF THE CARE
CONTINUUM
E. P. Ceppa1, H. A. Pitt2, A. Nakeeb1, C. M. Schmidt1,
N. J. Zyromski1, M. G. House1, B. Brand1, D. Weidert1 and
K. D. Lillemoe3
1Indiana University School Of Medicine, Indianapolis, IN;
2Temple University Health System, Philadelphia, PA;
3Massachusetts General Hospital, Bostom, MA
Background: Recent analyses of major gastrointestinal
operations document that postoperative complications are a
key driver of readmissions. However, successful programs to
reduce readmissions after major operations have not been
reported. This analysis documents a series of steps that were
implemented to reduce complications and readmissions fol-
lowing pancreatectomy.
Methods: From July 2007 through June 2012, the 30-day
readmission rate for patients undergoing proximal, distal and
total pancreatectomy was measured. Length of stay and mor-
tality indices were risk-adjusted by the University Health
Consortium. In 2008, a multifactorial effort was undertaken
which resulted in fewer surgical site infections. In 2010, a
Readmissions Team of surgeons, nurses, advanced providers,
pharmacists, social workers and care managers was formed.
Discharges with home care were increased from 20 to 50%,
and relationships with post-acute care facilities were
strengthened. In 2011, “Project RED” (ReEngineering Dis-
charges) was adopted and included a “discharge coach” to
assure that patients were ready for discharge and had
follow-up care. Statistical analysis included control charts
and Fischer’s Exact tests.
Results: Over five years, 1,147 patients underwent proximal
(69%), distal (26%) or total pancreatectomy (5%). The mor-
tality index (observed/expected rate) was 0.73 and did not
vary significantly over time. The length of stay (LOS) index
(observed/expected days) and 30-day all-cause readmission
rates are presented in the table.
Conclusion: All-cause readmissions following pancreatec-
tomy can be reduced without altering length of stay. Efforts
by surgeons to reduce complications as well as care coordi-
nation by nurses, advanced providers, pharmacists, social
workers, care managers and a “discharge coach” are required
to reduce readmissions.
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LO-B.03 PATENCY RATES OF PORTAL
VEIN/SUPERIOR MESENTERIC VEIN
RECONSTRUCTION AFTER
PANCREATECTOMY FOR PANCREATIC
ADENOCARCINOMA
A. N. Krepline, K. Duelge, K. K. Christians, B. George,
P. Ritch, B. Erickson, A. Mahmoud, E. J. Quebbeman,
K. K. Turaga, F. M. Johnston, T. C. Gambliin,
D. B. Evans and S. Tsai
Medical College Of Wisconsin, Milwaukee, WI
Background: The frequency of venous reconstruction (VR)
to facilitate a complete resection of pancreatic adenocarci-
noma (PC) has increased. Few studies have examined the
long-term patency of the SMV-PV after reconstruction.
Methods: From 2007–2013, patients (pts) with resectable
and borderline resectable PC who underwent resection with
VR were identified and classified by type of reconstruction.
Postoperative imaging, performed at 3-month intervals, was
reviewed to assess patency of VR from the time of surgery to
the date of last follow-up. Demographic and clinicopatho-
logic data were abstracted.
Results: VR was performed in 47 pts and the median
follow-up was 22 months. Techniques for VR and repair
included: tangential resection with primary repair (9
[19.1%]) or saphenous vein patch (SVP; 11 [23.4%]), seg-
mental resection with primary anastomosis (15 [31.9%]), or
internal jugular vein interposition (IJV;12 [25.5%]). Follow-
ing hospital discharge, 46 (97.7%) pts received prophylactic
anticoagulation or anti-platelet therapy including low-
molecular-weight heparin (n = 4, 8.7%), warfarin (n = 3,
6.5%), 81 mg aspirin (n = 8, 17.4%), or 325 mg aspirin
(n = 31, 61.7%). Of the 47 pts, 4 (8.5%) developed thrombo-
sis of the SMV-PV; 2 pts required segmental resection with
primary anastomosis (1) or interposition grafting (1) and
received prophylactic LMWH and 2 pts had SVP and
received 325 mg aspirin. Time to development of thrombosis
ranged from 16–238 days after surgery with 2 pts developing
thrombosis 2 and 3 months after surgery.
Conclusion: The majority of venous reconstructions remain
patent at a median of 2 year follow-up. The optimal
pharmacologic therapy to prevent venous thrombosis
requires further study.
LO-B.04 PANCREATIC TRAUMA IN THE
UNITED STATES: A CONTEMPORARY
APPRAISAL
B. R. Englum, A. M. Ganapathi, P. J. Speicher and
J. E. Scarborough
Duke University School Of Medicine, Dept. Of Surgery,
Durham, NC
Purpose: Management and outcomes in hepatopancreatic
trauma have been examined in small, single-institution
studies and older, multi-institutional databases; however,
large, contemporary studies examining national outcomes
with trauma-specific clinical details are lacking.
Methods: The National Trauma Data Bank (NTDB) com-
prises trauma data from >900 hospitals in the US. We iden-
tified adult patients from 2007–2011 with blunt or
penetrating injury. Patients with ICD-9 codes for hepatic or
pancreatic injury were analyzed. Descriptive tables com-
pared blunt and penetrating traumas. After excluding emer-
gency department deaths, mortality was compared by
management strategy.
Results: The NTDB contained 2.5 million patients meeting
inclusion criteria, with 79,154 (3.1%) hepatic injuries and
8,073 (0.3%) pancreatic injuries. Penetrating injury rates
were 22.8% and 38.1% for hepatic and pancreatic traumas,
respectively. A third of penetrating hepatic trauma required
repair. More than 25% of penetrating pancreatic trauma
required resection, while repair and drainage were performed
in 16.1% and 6.5%, respectively. Nearly 40%-50% of
hepatopancreatic traumas suffered complications (Table).
Mortality rates for hepatic and pancreatic traumas were
14.9% and 20.3%, respectively. Hepatic trauma patients
managed with non-operative or drainage therapy had
improved mortality (5.8%-6.7%) compared to those under-
going resection or repair (mortality of 17.1%-23.9%). Mor-
tality rates were 7.4% for pancreatic injuries managed with
drainage versus >15% in those requiring repair or resection
(Figure).
Conclusion: Despite advances in management of
hepatopancreatic trauma, mortality remains elevated in a
large, contemporary, trauma-specific dataset. Unadjusted
analysis suggests less aggressive surgical management, when
possible, may provide improved outcomes.
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LO-B.05 DEFINING THE
POSTOPERATIVE MORBIDITY INDEX
FOR DISTAL PANCREATECTOMY
M. K. Lee1, R. S. Lewis2, S. Strasberg1, B. L. Hall1,
P. Study Group2 and C. M. Vollmer2
1Washington University In St. Louis School Of Medicine,
St. Louis, MISSOURI; 2Perelman School Of Medicine,
Philadelphia, PA
Objective: Accurate assessment of complications is critical
in reporting and analyzing surgical outcomes effectively. The
Postoperative Morbidity Index (PMI), derived from the
Modified Accordion Severity Grading System and ACS-
NSQIP, is a quantitative measure of postoperative morbidity.
This study utilizes PMI to establish the unadjusted compli-
cation burden for distal pancreatectomy (DP).
Methods: Nine centers contributed ACS-NSQIP complica-
tion data for 655 DPs from 2005–2011. Each complication
was assigned an Accordion severity weight ranging between
0.11 for grade 1 to 1.00 for grade 6 (death). The PMI is the
sum of complication severity weights divided by the total
number of patients and can range from 0 (no complication in
any patient) to 1.000 (all patients died). Contribution of each
complication grade to burden is displayed as a severity
“spectrogram.”
Results: ACS-NSQIP complications occurred in 177
patients (27.0%). The non risk-adjusted PMI for DP is 0.087,
and for complication-bearing cases was 0.322. Bleeding/
Transfusion and Organ Space Infection were the most
common complications, both occurring in 7.2% of cases.
Frequency and burden differed across Accordion grades
(Figure). Grade 2 complications were highest in both fre-
quency and burden. While major complications (grades
4/5/6) represented only 14.9% of complication occurrences,
they accounted for 31.0% of the burden. Subgroup analysis
reveals how PMI can assess technical aspects of DP (Table).
On multivariate analysis, independent predictors for PMI
include: functional status, BMI, alcohol intake, neurologic
disease, and preop-SGOT.
Conclusion: PMI analysis establishes the morbidity burden
of DP, allowing for quantitative comparisons between
pancreatic resections, other operations, institutions, and
surgeons.
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LO-B.06 THE ROLE OF HEPATIC
ARTERY LYMPH NODE METASTASIS IN
PANCREATIC CANCER: PROGNOSTIC
FACTOR OR SURGICAL SELECTION
CRITERIA
P. Philips, S. C. Agle, C. R. Scoggins and R. C. Martin
University Of Louisville, Louisville, KY
Background: Presence of lymphatic metastasis is an inde-
pendent adverse prognostic factor in pancreatic cancer
(PDAC). Hepatic artery lymph node (HALN) metastasis
reportedly should be a contraindication to resection since it
confers a worse overall survival.
Methods: We identified consecutive patients between
2002–2012 who underwent PD for PDAC from our
prospective-hepato-pancreatico-biliary database. Overall
(OS) and disease-free survival (DFS) were estimated by
Kaplan–Meier test. Log-rank test and multivariate Cox-
proportional-hazards-regression model were used to investi-
gate clinio-pathological variables’ association with survival.
Results: A total of 420 patients underwent PD during this
period, of which 241 had HALN evaluation. They were
subcategorized into LN negative(LN-, n = 50, 20.7%),
peripancreatic LN (PPLN) positive,HALN negative
(HALN-/PPLN+, n = 150, 62, 2%) and PPLN+/HALN+
(n = 41, 17%). HALN was the only site of LN metastasis in
only 3 patients (1.2%). Median Follow-up was 13.5 months
(IQR 4.1–28.2). Median OS and DFS were 21.6 months
(95% CI: 17–25) and 12.4 months (95% CI: 9–14). On
univariate analysis, positive LN status, higher T-stage, higher
histological grade and perineural invasion (PNI) were asso-
ciated with significantly worseOS. On multivariate analysis,
hazard ratio(HR) of death was highest among HALN+/
PPLN+, then HALN-/PPLN+ (p = 0.04) and PNI patients
(p = 0.02). Similarly, HALN-/PPLN+ and HALN+/PPLN+
(p = 0.01) were the only predictors of worse DFS on Multi-
variate analysis (See table-1). Among LN positive patients,
there was no significant difference in medianOS for HALN
positive patients (18.4 months, 95% CI: 12.3–24) compared
to HALN negative group(19.7 months, 95% CI: 16.7–22.6,
p = 0.7).
Conclusion: Lymph node positive disease is an adverse
independent prognostic factor in pancreatic cancer, regard-
less of HALN involvement. Among lymph node positive
PDAC after PD, survival is comparable regardless of HALN
status. Therefore HALN positive disease should not preclude
the performance of PD
LO-B.07 PROPHYLACTIC OCTREOTIDE
FOR PANCREATODUODENECTOMY:
MORE HARM THAN GOOD?
M. T. McMillan1, J. D. Christein2, M. P. Callery3,
S. W. Behrman4, J. A. Drebin1, T. S. Kent3, B. C. Miller1,
R. S. Lewis1 and C. M. Vollmer1
1University Of Pennsylvania, Philadelphia, PA; 2University
Of Alabama At Birmingham Medical Center, Birmingham,
AL; 3Beth Israel Deaconess Medical Center, Boston, MA;
4University Of Tennessee Health Science Center, Memphis,
TN
Introduction: The accrued evidence regarding prophylactic
octreotide for pancreatoduodenectomy (PD) predates the
advent of the ISGPF classification system for postoperative
pancreatic fistula (POPF), and its efficacy in the setting of
high POPF risk is unknown. The Fistula Risk Score (FRS)
predicts the risk and impact of clinically-relevant fistulas
(CR-POPF) and can be useful in assessing the impact of
octreotide in scenarios of risk.
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Methods: From 2001–2013, 1018 PDs were performed at
four institutions, with prophylactic octreotide administered at
the surgeon’s discretion. The FRS and the Postoperative
Morbidity Index (PMI) were used to analyze occurrence and
burden of POPF across various risk scenarios.
Results: Overall, 391 patients (38.4%) received octreotide.
Without risk adjustment, POPFs occurred more frequently in
those who received octreotide (28.1% vs. 21.5%; P = 0.017).
Octreotide administration correlated with higher PMI and
increased hospital Duration of Stay (13.4 vs. 10.9 d;
p < 0.001). Octreotide significantly diminished the incidence
of Grade A (biochemical) POPFs (7.16% vs. 14.51%;
Figure). Conversely, CR-POPF actually occurred more often
when octreotide was used (21.0% vs.7.0%; p < 0.001), espe-
cially when there was advanced FRS risk (Table). Regression
analysis, controlling for FRS risk, demonstrates that
CR-POPF rates correspond with how often individual sur-
geons used octreotide.
Conclusion: This multi-institutional study, using ISGPF
criteria, evaluates POPF development across the entire risk
spectrum. While octreotide improves biochemical fistula
rates, it appears to offer no benefit in preventing CR-POPF.
Furthermore, it may potentiate CR-POPF development in the
presence of risk factors. This comprehensive analysis sug-
gests octreotide should not be utilized as a POPF mitigation
strategy.
LO-B.08 INTERNATIONAL CONSENSUS
GUIDELINE PARAMETERS CARRY
UNEQUAL WEIGHT AND ARE NOT
CUMULATIVE IN INTRADUCTAL
PAPILLARY MUCINOUS NEOPLASM
MALIGNANT RISK PREDICTION
A. M. Roch1, E. P. Ceppa1, J. M. DeWitt2,
M. A. Al-Haddad2 and C. M. Schmidt1
1Department of Surgery, Indiana University School Of
Medicine, Indianapolis, IN; 2Department Of Medicine,
Division Of Gastroenterology, IU Health University
Hospital, Indianapolis, IN
Introduction: The International Consensus Guidelines
(ICG) stratify malignant risk in patients with Intraductal
Papillary Mucinous Neoplasm (IPMN) into 3 progressive
categories: “no worrisome features”(NO), “worrisome
features”(WF) and “high risk stigmata”(HR). Hypothesis:
Type (clinical versus radiologic) and quantity of ICG WF and
HR carry unequal weight and are not cumulative in
malignant/invasive IPMN risk prediction.
Methods: A retrospective review of a prospectively main-
tained database of patients who underwent surgical resection
for IPMN at a single, university-based, medical center
(1992–2012) was performed. P < 0.05 was significant.
Results: Of 362 patients, 340 were eligible and categorized
as 70 NO, 185 WF, 85 HR. WF had more malignant/invasive
IPMN versus NO (27% vs. 4%, p = 0.001 and 16% vs. 4%,
p = 0.02). HR had more malignant/invasive IPMN versus WF
(57% vs. 27%, p = 0.0001 and 42% vs. 16%, p = 0.0001).
When radiological parameters only were considered for WF
versus HR, no difference was found in malignant/invasive
IPMN rate. Contrarily, when clinical parameters only were
considered, HR had more malignant/invasive IPMN (67% vs.
8%, p = 0.04 and 67% vs. 3%, p = 0.01). Malignant but not
invasive IPMN increased with the quantity of WF
(p = 0.001). Quantity of HR had no effect on malignancy/
invasive rate.
Conclusion: Type and quantity of ICG WF and HR carry
unequal weight and are not cumulative in malignant/invasive
IPMN risk prediction. Clinical parameters, in general, are
more predictive and should carry more weight in surgical
decision making. The quantity of WF is cumulative for
malignant IPMN risk prediction, but there is no cumulative
impact of the quantity of HR.
LO-B.09 UPREGULATION OF
S1P-RECEPTOR-1 IN PANCREATIC
DUCTAL ADENOCARCINOMA
A. Cardenas1, D. Cucher1, T. Jie2, R. Heimark1,3 and
E. Ong2
1University Of Arizona College Of Medicine – Department
Of Surgery, Tucson, AZ; 2University Of Arizona College Of
Medicine – Department Of Surgery – Hepatobiliary
Surgery, Tucson, AZ; 3University Of Arizona Cancer
Center, Tucson, AZ
Background: Sphingosine-1-phosphate (S1P) is a lipid sig-
naling molecule that promotes growth and migration and
inhibits apoptosis through activation of trans-membrane
receptors. Expression of the receptor S1PR1 is increased in
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cancer. S1P is generated from sphingosine by two kinases,
Sphk1 and Sphk2. Altered cytoplasmic/nuclear localization
of these kinases in malignant cells is associated with tumor
aggressiveness and worse prognosis. We hypothesized that
S1PR1 expression would be increased in pancreatic ductal
adenocarcinoma (PDAC) in association with altered
cytoplasmic/nuclear localization of sphingosine kinase 1
and 2.
Methods: Western blot analysis was used to determine
S1PR1, Sphk1 and Sphk2 expression in PDAC cell lines.
Cytoplasmic and nuclear localization was characterized by
biochemical isolation and blotting. Expression of these mol-
ecules in 21 FFPE samples of human PDAC was determined
using immunohistochemistry techniques.
Results: S1PR1 was strongly expressed in PDAC cell lines,
but not in non-malignant pancreatic ductal epithelium cells
(Fig. 1A). Altered localization of both Sphk1 and Sphk2 was
observed in PDAC cell lines (Fig. 1B). S1PR1 was expressed
in 76% of human PDAC samples. Nuclear localization of
Sphk1 and Sphk2 was detected in 22.2% and 47.6% of the
samples.
Conclusion: S1PR1 is highly expressed in vitro and in vivo
in PDAC, but not in normal pancreatic ductal epithelium.
Sphingosine kinase subcellular localization is similarly
altered in PDAC. This implies that S1P signaling is altered in
cancer, and further study will elucidate the downstream
pathway. Inhibition of S1P receptors and/or kinases may be a
viable treatment strategy for metastatic PDAC in conjunction
with chemotherapy.
LO-B.10 A STANDARDIZED CARE PLAN
IS ASSOCIATED WITH SHORTER
HOSPITAL LENGTH OF STAY IN
PATIENTS UNDERGOING
PANCREATICODUODENECTOMY
D. P. Nussbaum1, K. Penne1, P. J. Speicher1, S. S. Stinnett2,
A. Cocieru1, D. G. Blazer1, S. Zani1, B. M. Clary1,
D. S. Tyler1 and R. R. White1
1Duke University Department Of Surgery, Durham, NC;
2Duke University Department Of Biostatistics &
Bioinformatics, Durham, NC
Introduction: Standardized Care Plans (SCPs) have gained
popularity in pancreatic surgery, yet outcomes data are
limited. Our institution introduced a SCP in 1/2011 which
included a fast-track recovery pathway (FTRP) and the selec-
tive placement of feeding jejunostomy tubes (FJTs).
Methods: A retrospective review of 242 consecutive
patients undergoing pancreaticoduodenectomy between
2008–2012 was completed. Patients were stratified by
SCP implementation. Univariate comparison followed by
multivariable linear regression were performed to identify
predictors of hospital length of stay (HLOS).
Results: SCP patients (n = 100) were slightly older but
otherwise similar to pre-SCP patients (n = 142). FJT place-
ment occurred less frequently in SCP patients (38 vs. 94%,
p < 0.001). All SCP patients were initiated on the FTRP.
Complication rates (Clavien-Dindo grade ≥ 3) were similar
(41 vs. 43%, p = 0.79). Among SCP patients, an oral diet was
introduced earlier (5 vs. 8.5 days, p < 0.001) and HLOS was
shorter (11 vs. 13 days, p = 0.01). There were no differences
in readmission, reoperation, or mortality rates. Following
adjustment with multivariable linear regression, we con-
firmed SCP status as an independent predictor of HLOS (-0.9
days, p = 0.047). Vascular reconstruction was the only other
independent predictor of HLOS (+1.3 days, p = 0.002). In
exploratory analysis to assess SCP components, HLOS was
further evaluated based on FTRP status and FJT placement.
Although both factors were highly associated with HLOS,
neither was independently predictive in multivariable analy-
sis (Table 1).
Conclusion: Implementation of a SCP resulted in shorter
HLOS without an increase in readmissions. Future studies
are necessary to identify the individual components of SCPs
that most influence outcomes.
Abstracts 15
© 2014 The Authors
HPB © 2014 Americas Hepato-Pancreato-Biliary AssociationHPB 2014, 16 (Suppl. 1), 1–99
